FDA Approves New Kyprolis® (carfilzomib) combination therapy for the treatment of patients with RRMM.

Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy. Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval.

Source: International Myeloma Foundation - January 25, 2016 Category: Hematology Source Type: news